0R1D.LSE Sangamo Therapeutics, Inc.
- Market cap
- -
- P/E
- -
- P/B
- -
- ROE
- -
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 1 quarter up to Mar 2026.
Is 0R1D.LSE undervalued?
Graham numberThe Graham number of Sangamo Therapeutics, Inc. cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Sangamo Therapeutics, Inc. fundamental analysis
No fundamental analysis for Sangamo Therapeutics, Inc. yet.
Sangamo Therapeutics, Inc. stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Sangamo Therapeutics, Inc.
Sangamo Therapeutics, Inc., a clinical-stage genomic medicine company, focuses on translating science into medicines that transform the lives of patients and families afflicted with serious diseases in the United States. The company's clinical-stage product candidates are ST-920, a gene therapy product candidate, which is in Phase 1/2 clinical study for the treatment of Fabry disease; small fiber neuropathy for chronic neuropathic pain, and prion disease; Phase 1/2 clinical …
Full company profileSangamo Therapeutics, Inc. financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 1 quarter up to Mar 31, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Sangamo Therapeutics, Inc. annual financial statements
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 19.4M | 36.6M | 84.5M | 102M | 118M | 111M | 111M | 176M | 57.8M | 39.6M | 5.77M |
| Gross Profit | -46.2M | -29.2M | -30.4M | -43.5M | -62.5M | 101M | 99.2M | -45.3M | 48.4M | 32.0M | 2.97M |
| Operating Income | -72.6M | -56.4M | -75.1M | -105M | -130M | -183M | -201M | -274M | -99.1M | -108M | -128M |
| EBITDA | -70.7M | -54.9M | -66.5M | -101M | -115M | -174M | -189M | -241M | -88.7M | -100M | -125M |
| Net Income | -71.7M | -54.6M | -68.3M | -95.2M | -121M | -178M | -192M | -258M | -97.9M | -123M | -124M |
| EPS | -1.02 | -0.70 | -0.70 | -0.85 | -0.90 | -1.23 | -1.25 | -1.48 | -0.49 | -0.44 | -0.32 |
| Balance Sheet | |||||||||||
| Total Assets | 158M | 287M | 590M | 638M | 939M | 722M | 563M | 165M | 105M | 60.5M | 60.0M |
| Total Liabilities | 21.7M | 98.8M | 223M | 205M | 441M | 347M | 268M | 82.4M | 82.5M | 74.8M | 78.9M |
| Shareholders' Equity | 136M | 188M | 367M | 433M | 498M | 375M | 295M | 82.9M | 22.8M | -14.3M | -19.0M |
| Cash & Short-term Investments | 143M | 243M | 400M | 362M | 641M | 377M | 278M | 81.0M | 41.9M | 20.9M | 27.6M |
| Total Debt | 3.95M | 24.7M | 27.7M | 44.4M | -210M | 48.1M | 43.1M | 38.1M | 30.6M | 26.8M | 19.3M |
| Cash Flow | |||||||||||
| Operating Cash Flow | -65.9M | 11.2M | 37.2M | -144M | 170M | -233M | -224M | -225M | -67.1M | -97.2M | -77.1M |
| Capital Expenditure | 732K | 3.75M | 43.1M | 20.7M | 14.7M | 23.3M | 20.2M | 21.2M | 267K | 102K | 52.0K |
| Free Cash Flow | -66.6M | 7.43M | -5.91M | -165M | 155M | -257M | -244M | -246M | -67.4M | -97.3M | -77.2M |
| Ratios | |||||||||||
| ROE | -52.6% | -29.0% | -18.6% | -22.0% | -24.3% | -47.5% | -65.2% | -311.1% | -430.1% | - | - |
| ROA | -45.4% | -19.0% | -11.6% | -14.9% | -12.9% | -24.7% | -34.2% | -156.0% | -93.0% | -203.1% | -206.8% |
| Net Profit Margin | -369.6% | -149.2% | -80.9% | -92.9% | -102.4% | -161.1% | -172.8% | -146.3% | -169.4% | -310.8% | -2,149.4% |
| Debt to Equity | 0.03x | 0.13x | 0.08x | 0.10x | -0.42x | 0.13x | 0.15x | 0.46x | 1.34x | - | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Sangamo Therapeutics, Inc. dividends
Sangamo Therapeutics, Inc. has not paid dividends in the last 9 fiscal years.
Who owns Sangamo Therapeutics, Inc.
- Insiders 0.93%
- Institutions 9.58%
- Public & others 89.49%
- Free float 364M
Sangamo Therapeutics, Inc. company profile
- Company name
- Sangamo Therapeutics, Inc.
- Ticker
- 0R1D.LSE
- Exchange
- London Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 142
- Fiscal year end
- December
- Address
- 501 Canal Blvd, Richmond, CA, United States, 94804
- Phone
- 510 970 6000
- Website
- sangamo.com
About Sangamo Therapeutics, Inc.
Sangamo Therapeutics, Inc., a clinical-stage genomic medicine company, focuses on translating science into medicines that transform the lives of patients and families afflicted with serious diseases in the United States. The company's clinical-stage product candidates are ST-920, a gene therapy product candidate, which is in Phase 1/2 clinical study for the treatment of Fabry disease; small fiber neuropathy for chronic neuropathic pain, and prion disease; Phase 1/2 clinical trial to evaluate the safety and tolerability of the investigational genetically modified cell therapy TX200 in patients undergoing a kidney transplant.; SB-525, a gene therapy product candidate, which is in Phase 3 clinical trial for the treatment of moderately severe to severe hemophilia A; giroctocogene fitelparvovec, a Phase 3 study to evaluate the clinical efficacy and safety of giroctocogene fitelparvovec gene therapy in adult male with moderately severe or severe hemophilia A. Sangamo Therapeutics, Inc. has collaborative and strategic partnerships with Genentech, Inc.; Astellas Gene Therapies, Inc.; Capsid Delivery License Agreement with Eli Lilly and Company; Alexion Pharmaceuticals, Inc. " ALS and Frontotemporal Lobar Degeneration; Takeda " Huntington's Disease; and other areas, such as plant agriculture and research reagents, including the production of transgenic animals and cell-line engineering with Corteva AgriScience and Open Monoclonal Technology, Inc. The company was formerly known as Sangamo BioSciences, Inc. and changed its name to Sangamo Therapeutics, Inc. in January 2017. The company was incorporated in 1995 and is headquartered in Richmond, California. On June 23, 2026, Sangamo Therapeutics, Inc. filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the District of Delaware.
Sangamo Therapeutics, Inc. management
7- Dr. Alexander D. Macrae Ch.B, M.B., MRCP, Ph.D.CEO, President & Director · born 1963
- Mr. Scott B. WilloughbySenior VP, Chief Legal Officer & Corporate Secretary · born 1975
- Dr. Nathalie Dubois-Stringfellow Ph.D.Senior VP & Chief Development Officer · born 1962
- Mr. Nikunj JainInterim CFO and Principal Financial & Accounting Officer · born 1980
- Mr. Phillip RamseyChief Technical Officer
- Ms. Stephanie J. Seiler CLPVP and Head of Business Development & Alliance Management
- Mr. David OjalaScientist II - Discovery & Translational Research